Dealing with time-dependent pharmacokinetics during the early clinical development of a new leukotriene B4 synthesis inhibitor

Pharmaceutical Research

Volumn 23, Issue 7, 2006, Pages 1533-1542

  Trocóniz, Iñaki F ^a   Zsolt, Ilonka ^b,c   Garrido, María J ^a   Valle, Marta ^b   Antonijoan, Rosa M ^b   Barbanoj, Manel J ^b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c Adasa Sistemas SAU   (Spain)

Author keywords

Metabolism autoinhibition; NONMEM; Population pharmacokinetics

Indexed keywords

2,4,6 TRIIODOPHENOL; AM 24; LEUKOTRIENE B4; PHENOL DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; COMPUTER PROGRAM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; ENZYME METABOLISM; ENZYME SYNTHESIS; FATTY ACID SYNTHESIS; HUMAN; MALE; METABOLIC INHIBITION; NONLINEAR SYSTEM; NORMAL HUMAN; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ARACHIDONATE 5-LIPOXYGENASE; BIOLOGICAL AVAILABILITY; COMPUTER SIMULATION; ENZYME INHIBITORS; HUMANS; INTESTINAL ABSORPTION; LEUKOTRIENE B4; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; PHENOLS; RANDOMIZED CONTROLLED TRIALS;

EID: 33745061845     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-006-0254-1     Document Type: Article

References (27)

1. R. A. Prentis Y. Lis S. R. Walker 1988 Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985) Br. J. Clin. Pharmacol. 25 387 396
2. D. K. Walker 2004 The use of pharmacokinetic and pharmacodynamic data in the assessment of drug safety in early drug development Br. J. Clin. Pharmacol. 58 601 608
3. B. Y. Kim J. H. Jeong K. Park J. D. Kim 2005 Bioadhesive interaction and hypoglycemic effect of insulin-loaded lectin-microparticle conjugates in oral insulin delivery system J. Control. Release 102 525 538
4. I. Echevarria C. Barturen M. J. Renedo I. F. Troconiz M. C. Dios-Vieitez 2000 Comparative pharmacokinetics, tissue distributions, and effects on renal function of novel polymeric formulations of amphotericin B and amphotericin B-deoxycholate in rats Antimicrob. Agents Chemother. 44 898 904
5. L. Aarons M. O. Karlsson F. Mentré F. Rombout J. L. Steimer A. van Peer invited COST B15 experts 2001 Role of modelling and simulation in Phase I development Eur. J. Pharm. Sci. 13 115 122
6. P. Olsson Gisleskog D. Hermann M. Hammarlund-Udenaes M. O. Karlsson 1998 The pharmacokinetic modelling of GII98745 (dutasteride) a compound with parallel linear and nonlinear elimination Br. J. Clin. Pharmacol. 47 53 58
7. M. Depre B. Friedman A. Van Hecken I. de Lepeleire I W. Tanaka A. Dallob S. Shingo A. Porras C. Lin P. J. de Schepper 1994 Pharmacokinetics and pharmacodynamics of multiple oral doses of MK-0591, a 5-lipoxygenase-activating protein inhibitor Clin. Pharmacol. Ther. 56 22 30
8. L. Garcia-Capdevila C. Lopez-Calull S. Pompermayer C. Arroyo A. M. Molins-Pujol J. Bonal 1998 High-performance liquid chromatography analysis of Bobel-24 in biological samples for pharmacokinetic, metabolic and tissue distribution studies J. Chromatogr. B Biomed. Sci. Appl. 708 169 175
9. S. L. Beal L. B. Sheiner 1992 NONMEM Users Guides NONMEM Project Group, University of California at San Francisco San Francisco, CA
10. K. S. Pang M. Rowland 1977 Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance J. Pharmacokinet. Biopharm. 5 625 653
11. P. O. Gisleskog D. Hermann M. Hammarlund-Udenaes M. O. Karlsson 1999 The pharmacokinetic modeling of GI198745 (dutasteride), a compound with parallel linear and nonlinear elimination Br. J. Clin. Pharmacol. 47 53 58
12. H. C. Porchet N. L. Benowitz L. B. Sheiner 1988 Pharmacodynamic model of tolerance: application to nicotine J. Pharmacol. Exp. Ther. 244 231 236
13. C. von Bahr E. Steiner Y. Koike J. Gabrielsson 1998 Time course of enzyme induction in humans: effect of pentobarbital on nortriptyline metabolism Clin. Pharmacol. Ther. 64 18 26
14. J. W. Mandema D. Verotta L. B. Sheiner 1992 Building population pharmacokinetic-pharmacodynamic models. I. Models for covariate effects J. Pharmacokinet. Biopharm. 20 511 528
15. E. N. Jonsson M. O. Karlsson 1999 Xpose: an Splus based population pharmacokinetic/pharmacodynamic model building aid for NONMEM Comput. Methods Programs Biomed. 58 51 64
16. T. M. Ludden S. L. Beal L. B. Sheiner 1994 Comparison of the Akaike information criterion, the Schwarz criterion and the F test as guides to model selection J. Pharmacokinet. Biopharm. 22 431 445
17. M. Gardmark L. Brynne M. Hammarlund-Udenaes M. O. Karlsson 1999 Interchangeability and predictive performance of empirical tolerance models Clin. Pharmacokinet. 36 145 167
18. T. Kerbusch P. A. Milligan M. O. Karlsson 2004 Assessment of the relative in vivo potency of the hydroxylated metabolite of darifenacin in its ability to decrease salivary flow using pooled population pharmacokinetic-pharmacodynamic data Br. J. Clin. Pharmacol. 57 170 180
19. J. M. Gries N. Benowitz D. Verotta 1998 Importance of chronopharmacokinetics in design and evaluation of transdermal drug delivery systems J. Pharmacol. Exp. Ther. 285 457 463
20. M. Hassan U. S. Svensson P. Ljungman B. Bjorkstrand H. Olsson M. Bielenstein M. Abdel-Rehim C. Nilsson M. Johansson M. O. Karlsson 1999 A mechanism-based pharmacokinetic-enzyme model for cyclophosphamide autoinduction in breast cancer patients Br. J. Clin. Pharmacol. 48 669 677
21. A. D. Huitema R. A. Mathot M. M. Tibben S. Rodenhuis J. H. Beijnen 2001 A mechanism-based pharmacokinetic model for the cytochrome P450 drug-drug interaction between cyclophosphamide and thioTEPA and the autoinduction of cyclophosphamide J. Pharmacokinet. Pharmacodyn. 28 211 230
22. M. E. de Jonge A. D. Huitema S. Rodenhuis J. H. Beijnen 2004 Integrated population pharmacokinetic model of both cyclophosphamide and thiotepa suggesting a mutual drug-drug interaction J. Pharmacokinet. Pharmacodyn. 31 135 156
23. P. L. Bonate S. Floret C. Bentzen 2004 Population pharmacokinetics of APOMINE: a meta-analysis in cancer patients and healthy males Br. J. Clin. Pharmacol. 58 142 155
24. A. C. Collier J. A. Keelan P. E. Van Zijl J. W. Paxton M. D. Mitchell M. D. Tingle 2004 Human placental glucuronidation and transport of 3′azido-3′-deoxythymidine and uridine diphosphate glucuronic acid Drug Metab. Dispos. 32 813 820
25. L. K. Solai B. G. Pollock B. H. Mulsant R. F. Frye M. D. Miller R. A. Sweet M. Kirshner D. Sorisio A. Begley C. F. Reynolds III 2002 Effect of nortriptyline and paroxetine on CYP2D6 activity in depressed elderly patients J. Clin. Psychopharmacol. 22 481 486
26. H. A. Welker H. Wiltshire R. Bullingham 1998 Clinical pharmacokinetics of mibefradil Clin. Pharmacokinet. 35 405 423
27. W. G. Tong X. Z. Ding R. Henning R. C. Witt J. Standop P. M. Pour T. E. Adrian 2002 Leukotriene B4 receptor antagonist LY293111 inhibits proliferation and induces apoptosis in human pancreatic cancer cells Clin. Cancer Res. 8 3232 3242